Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study-Reference-Cited by-同舟云学术

Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study

Published:2016-08-09 Issue:9 Volume:27 Page:1067-1079
ISSN:0957-5243
Container-title:Cancer Causes & Control
language:en
Short-container-title:Cancer Causes Control

Author:

Skriver Charlotte^ORCID,Dehlendorff Christian,Borre Michael,Brasso Klaus,Sørensen Henrik Toft,Hallas Jesper,Larsen Signe Benzon,Tjønneland Anne,Friis Søren

Funder

Kræftens Bekæmpelse (DK)

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10552-016-0785-7.pdf

Reference57 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi: 10.1002/ijc.29210

2. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15:e484–e492. doi: 10.1016/S1470-2045(14)70211-6

3. Patel AR, Klein EA (2009) Risk factors for prostate cancer. Nat Clin Pract Urol 6:87–95. doi: 10.1038/ncpuro1290

4. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507. doi: 10.1016/S1470-2045(09)70035-X

5. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47–57. doi: 10.1093/annonc/mdu225

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against TMPRSS2-ERG (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer;Cancers;2023-10-19

2. Effect of aspirin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from randomized controlled trials and real-world studies;European Journal of Clinical Pharmacology;2023-08-30

3. A systematic assessment of the association between frequently prescribed medicines and the risk of common cancers: a series of nested case-control studies;BMC Medicine;2021-01-26

4. Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis;Rheumatology;2020-05-23

5. The association between aspirin use and depression: a systematic review and meta‐analysis of observational studies;Pharmacoepidemiology and Drug Safety;2020-04-20